Prospectively Randomized Trial Using Perioperative Low Dose Octreotide to Prevent Organ Related and General Complications Following Pancreatic Surgery and Pancreatico-jejunostomy

Abstract

In patients undergoing pancreatic surgery and pancreatico-jejunostomy, the perioperative use of 3 x 0.1 mg Octreotide for 7 days does not reduce general complications nor fistula formation.